癌症或终末期疾病患者阿片类处方风险管理:无意忽视还是禁忌?
本文指出,在美国处方药滥用流行、慢性疼痛安全阿片处方指南陆续出台的背景下,针对癌症或终末期疾病患者疼痛的阿片处方指导仍然有限。现有研究提示,癌症患者的误用、滥用和成瘾风险比例与普通人群相近,而姑息治疗与临终关怀项目在评估或管理异常行为或药物滥用证据方面准备不足,亟需进一步研究与专业共识。
要点
- 癌症患者误用、滥用和成瘾风险与普通人群相近,不应默认其风险更低。
- 针对癌症或终末期疾病疼痛的阿片处方缺乏专门指导,现有指南多针对慢性疼痛。
- 姑息治疗与临终关怀项目对异常行为或药物滥用的评估与管理准备不足。
核心结论
- 癌症或终末期疾病患者的阿片处方风险管理缺乏专门指导,需进一步研究与专业共识。
研究设计与样本
- 本文为综述/观点类文章,围绕癌症或终末期疾病患者阿片处方的风险管理进行讨论。
主要发现
- 当前研究提示癌症患者的误用、滥用和成瘾风险比例与普通人群相近。
- 姑息治疗与临终关怀项目对异常行为或药物滥用证据的评估与管理准备不足。
临床怎么用
- 对癌症或终末期疾病患者处方阿片时,应像普通人群一样纳入误用、滥用和成瘾风险评估。
- 姑息治疗与临终关怀项目需加强异常行为和药物滥用的评估与管理能力。
局限性
- 本文未报告具体研究设计、样本量或定量数据,相关结论基于现有研究综述与观点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
As the United States experiences an epidemic of prescription drug abuse, and guidelines on safe practices in prescribing opioids in chronic pain have subsequently emerged from professional organizations and governmental agencies, limited guidance exists for prescribers of opioids to treat pain in patients with cancer or terminal illness. Patients with active cancer or terminal illness often have pain and are frequently prescribed opioids and other controlled substances. Current studies suggest that patients with cancer have similar rates of risk for misuse, abuse, and addiction as the general public. Moreover, palliative care and hospice programs appear poorly prepared for assessing or managing patients with aberrant behaviors or evidence of drug abuse. Further research and professional consensus are needed to help address the challenges associated with misuse, abuse, and addiction in patients with cancer and terminal illness.
引用
- Copenhaver DJ, Karvelas NB, Fishman SM, et al. Risk Management for Opioid Prescribing in the Treatment of Patients With Pain From Cancer or Terminal Illness: Inadvertent Oversight or Taboo? Anesth Analg. 2017. PMID: 29049111. doi:10.1213/ANE.0000000000002463
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。